- Home
- CNTB vs QVCG Comparison
CNTB vs QVCG Comparison
Compare CNTB & QVCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.90
N/A
Current Price
$9.04
Company Overview
Basic Information| Metric | CNTB | QVCG |
|---|---|---|
| Founded | 2012 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.4M | 123.2M |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CNTB | QVCG |
|---|---|---|
| Price | $0.90 | $9.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $5.88 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 262.4K |
| Earning Date | 11-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $64,000.00 | ★ $8,293,000,000.00 |
| Revenue This Year | $11,291.47 | $9.11 |
| Revenue Next Year | $74.30 | $55.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $9.09 |
| 52 Week High | $3.82 | $18.32 |
Technical Indicators
Market Signals| Indicator | CNTB | QVCG |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 14.31 |
| Support Level | $0.85 | N/A |
| Resistance Level | $2.74 | $18.16 |
| Average True Range (ATR) | 0.08 | 1.09 |
| MACD | 0.03 | -0.45 |
| Stochastic Oscillator | 3.46 | 1.47 |
Price Performance
Historical Comparison CNTB
QVCG
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.